Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas

International Journal of Gynecological Cancer

Volumn 21, Issue 4, 2011, Pages 668-672

  Lee, Chae Hyeong ^a   Roh, Ju Won ^a   Choi, Jong Sun ^b   Kang, Sokbom ^c   Park, In Ae ^a   Chung, Hyun Hoon ^d   Jeon, Yong Tark ^d   Kim, Jae Weon ^d   Park, Noh Hyun ^d   Kang, Soon Beom ^d   Song, Yong Sang ^e  

^a Department of Obstetrics and Gynecology ^*  (South Korea)

^b Dongguk University College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

^d The Catholic University of Korea College of Medicine   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

Cyclooxygenase 2; Survival; Uterine leiomyosarcoma; Uterine sarcoma

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM SARCOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL; TUMOR VOLUME; UTERINE LEIOMYOSARCOMA; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 80051870801     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182150d56     Document Type: Article

References (23)

1. Platz CE, Benda JA. Female genital tract cancer. Cancer. 1995;75:270-294.
2. Livi L, Andreopoulou E, Shah N, et al. Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clin Oncol (R Coll Radiol). 2004;16:261-268. (Pubitemid 38696967)
3. Olah KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol. 1992;99:590-594.
4. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30:3-21. (Pubitemid 30078300)
5. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med. 2002;53:35-57. (Pubitemid 34177870)
6. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol. 2004;31:2-11. (Pubitemid 38879409)
7. Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res. 2002;62: 1567-1572. (Pubitemid 34407824)
8. Tatsuguchi A, Matsui K, Shinji Y, et al. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol. 2004;35:488-495. (Pubitemid 38507087)
9. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94:3336-3340. (Pubitemid 27157312)
10. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998; 93:705-716. (Pubitemid 28257578)
11. Bin W, He W, Feng Z, et al. Prognostic relevance of cyclooxygenase-2 (COX-2) expression in Chinese patients with prostate cancer. Acta Histochem. 2011;113:131-136.
12. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I nonYsmall cell lung cancer. Clin Cancer Res. 2001;7: 861-867. (Pubitemid 32708722)
13. Ogino S, Kirkner GJ, Nosho K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008;14:8221-8227.
14. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632-635. (Pubitemid 34126931)
15. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002;190: 279-286. (Pubitemid 34111968)
16. Seo SS, Song YS, Kang DH, et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol. 2004;92:927-935. (Pubitemid 38251398)
17. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000;60:293-297. (Pubitemid 30070754)
18. Cimbaluk D, Rotmensch J, Scudiere J, et al. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2007;105:138-144. (Pubitemid 46441450)
19. Matsumoto Y, Ishiko O, Sumi T, et al. Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions. Oncol Rep. 2001;8:1225-1227. (Pubitemid 33758718)
20. Menczer J, Schreiber L, Sukmanov O, et al. COX-2 expression in uterine carcinosarcoma. Acta Obstet Gynecol Scand. 2010;89:120-125.
21. Raspollini MR, Susini T, Amunni G, et al. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol. 2005;96:159-167. (Pubitemid 39612431)
22. Comunoglu NU, Durak H, Comunoglu C, et al. Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis. APMIS. 2007;115:726-735. (Pubitemid 46854992)
23. Raspollini MR, Amunni G, Villanucci A, et al. Cyclooxygenase-2 expression in uterine leiomyosarcomas. J Chemother. 2004;16:577-581.